Article Information
History
- May 26, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Carlos K.H. Wong, PhD1,2,3,†,
- Ivan C.H. Au, BSc1,
- Kristy T.K. Lau, MSc1,
- Eric H. Y. Lau, PhD3,4,
- Benjamin J. Cowling, PhD3,4,*,† and
- Gabriel M. Leung, M.D3,4,*
- 1Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
- 2Department of Family Medicine and Primary Care, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
- 3Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong SAR, China
- 4WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
- ↵†Corresponding authors:
Carlos King Ho Wong (carlosho{at}hku.hk), Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, 26 Sassoon Road, Pokfulam, Hong Kong SAR, China, Benjamin John Cowling (bcowling{at}hku.hk), World Health Organization Collaborating Center for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, China
Posted May 26, 2022.
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study
